Special Issue "Immuno-Metabolic Crosstalk in Oncogenesis"

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: 30 September 2021.

Special Issue Editor

Prof. Aksam J. Merched
E-Mail Website
Guest Editor
University of Bordeaux, Department of Health Sciences and INSERM U1035 (Biotherapy of Genetic, Inflammatory Diseases and Cancer), 146 rue Léo Saignat, 33076 Bordeaux cedex, France
Interests: metabolism; inflammation; immunosuppression; cancers; lipids; liver

Special Issue Information

Dear colleagues,

Altered cellular metabolism and immunosuppression in the tumor microenvironment became emerging hallmarks of cancer. Oncometabolites are needed to sustain tumor cell survival, growth, and proliferation by fulfilling the energetic needs and providing the raw materials and signaling molecules for many oncogenic pathways. Some are capable of driving immune cell polarization toward immunosuppressive and cancer-tolerant isotypes. The main focus of this Special Issue is the crosstalk between these two hallmarks in the context of oncogenesis. Decoding this subtle crosstalk at the molecular and cellular levels is a prerequisite for the discovery of more effective combinatory therapeutic approaches targeting immuno-metabolism of cancers.

I am seeking all topics relevant to metabolic defect, adaptation, nutritional addiction of cancer cells, and modulation of tumor-targeted immune responses.

I am looking forward to receiving your contribution.

Prof. Aksam J. Merched
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cancer
  • immune resolution
  • immunosuppression
  • immunoediting
  • immunotherapy
  • mitochondria
  • metabolism
  • oncometabolites
  • nutritional dependence
  • epigenetics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Open AccessCommunication
Alteration of Tissue Marking Dyes Depends on Used Chromogen during Immunohistochemistry
Cells 2021, 10(4), 835; https://doi.org/10.3390/cells10040835 - 08 Apr 2021
Viewed by 208
Pathological biopsy protocols require tissue marking dye (TMD) for orientation. In some cases (e.g., close margin), additional immunohistochemical analyses can be necessary. Therefore, the correlation between the applied TMD during macroscopy and the examined TMD during microscopy is crucial for the correct orientation, [...] Read more.
Pathological biopsy protocols require tissue marking dye (TMD) for orientation. In some cases (e.g., close margin), additional immunohistochemical analyses can be necessary. Therefore, the correlation between the applied TMD during macroscopy and the examined TMD during microscopy is crucial for the correct orientation, the residual tumour status and the subsequent therapeutic regime. In this context, our group observed colour changes during routine immunohistochemistry. Tissue specimens were marked with various TMD and processed by two different methods. TMD (blue, red, black, yellow and green) obtained from three different providers (A, B and C, and Whiteout/Tipp-Ex®) were used. Immunohistochemistry was performed manually via stepwise omission of reagents to identify the colour changing mechanism. Blue colour from provider A changed during immunohistochemistry into black, when 3,3′-Diaminobenzidine-tetrahydrochloride-dihydrate (DAB) and H2O2 was applied as an immunoperoxidase-based terminal colour signal. No other applied reagents, nor tissue texture or processing showed any influence on the colour. The remaining colours from provider A and the other colours did not show any changes during immunohistochemistry. Our results demonstrate an interesting and important pitfall in routine immunohistochemistry-based diagnostics that pathologists should be aware of. Furthermore, the chemical rationale behind the observed misleading colour change is discussed. Full article
(This article belongs to the Special Issue Immuno-Metabolic Crosstalk in Oncogenesis)
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Gliomas: relationship between metabolism and microenvironment
Authors: Ainhoa Hernández; Ana M. Muñoz-Mármol; Cristina Carrato; Marta Domenech; Carmen Balana
Affiliation: 1Institut Catala d’Oncologia (ICO) Badalona, Badalona Applied Research Group in Oncology (B- ARGO Group), Institut Investigació Germans Trias i Pujol (IGTP), Badalona, Spain 2Pathology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Abstract: /

Title: Tumour metabolism in myeloid-driven immunosuppression
Authors: Thomas Boyer1; Céline Blaye1,2; Nicolas Larmonier1,3; Charlotte Domblides1,4
Affiliation: 1. CNRS UMR5164, ImmunoConcEpT, Bordeaux, France 2. Department of Medical Oncology, Bergonie Institute, Bordeaux, France 3. Department of Life and Medical Sciences, University of Bordeaux, Bordeaux, France 4. Department of Medical Oncology, Hôpital Saint-André, University Hospital Bordeaux, France
Abstract: Tumour metabolism plays a crucial role in sustaining tumorigenesis. Increasing reports highlight the role of tumour metabolism in the control of immune cell functions, generating a potent immunosuppressive contexture leading to immune escape. The metabolic reprogramming of tumour cells and the immune escape are two major hallmarks of cancer, with several cross talks between them. Here, we propose to review the effect of tumour metabolism on immune cells focusing on myeloid-cells, due to their important role in tumorigenesis and immunosuppression, from the early stages of the disease. We will also discuss about ways to target this specific crosstalk in cancer patients.

Title: Immuno-metabolic modulation of liver oncogenesis by the tryptophan
Authors: Véronique Trézéguet-Busquet; Hala Fatrouni; Aksam Merched
Affiliation: Bordeaux University and Inserm U 1035, Biotherapy of Genetic, Inflammatory Diseases and Cancer (BMGIC), MiRCade Team; Bordeaux, France.
Abstract: Metabolic rewiring in tumor cells is a major hallmark of oncogenesis. Some of the oncometabolites drive suppressive and tolerogenic signals from the immune system, which becomes complicit to the advent and the survival of neoplasia. Tryptophan catabolism through the kynurenin (Kyn) pathway was reported to play immunosuppressive actions across many types of cancer. Extensive debate of whether the culprit of immunosuppression was the depletion of Trp or rather Kyn accumulation in the tumor microenvironment has been ongoing for years. Results from clinical trials assessing the benefit of inhibiting key limiting enzymes of this pathway such as indoleamine 2,3-dioxygenase (IDO1) failed to meet the expectations. Bearing in mind the complexity of the tumoral terrain and the existence of different cancers with IDO1/TDO expressing and non-expressing tumoral cells, here we present a comprehensive analysis of the trp global metabolic hub and the driving potential of the process of oncogenesis with main focus on liver cancers.

Back to TopTop